Circulating MicroRNA-21 Correlates With Left Atrial Low-Voltage Areas and Is Associated With Procedure Outcome in Patients Undergoing Atrial Fibrillation Ablation

Zhou, Qifeng; Maleck, Carole; Ungern‐Sternberg, Saskia N. I. von; Neupane, Balram; Heinzmann, David; Marquardt, Jonathan; Duckheim, Martin; Scheckenbach, Christian; Stimpfle, Fabian; Gawaz, Meinrad; Schreieck, Jürgen; Seizer, Peter; Gramlich, Michael

doi:10.1161/circep.118.006242

Cited by 54 publications

(47 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Participants with AF had lower plasma levels of miR-21 compared to controls, and miR-21 expression increased 1 month after catheter ablation 7 . The circulating miR-21 level is also associated with AF ablation results in patients with persistent AF undergoing ablation (and this level correlates with left atrial low voltage areas) 8 . Other studies have shown higher levels of miRNAs 125a, 10b, 601, 30a-3p, and 199b in patients with 12-month AF recurrences after catheter ablation than in patients without AF recurrences 9 .…”

Section: Discussionmentioning

confidence: 99%

Serum microRNA in patients undergoing atrial fibrillation ablation

Kiliszek

Maciak

Maciejak

et al. 2020

Sci Rep

View full text Add to dashboard Cite

MicroRNAs mediate posttranscriptional gene regulation. The aim of the study was to find a microRNA predictor of successful atrial fibrillation (AF) ablation. A total of 109 patients undergoing first-time AF ablation were included. Nineteen patients were selected to undergo serum microRNA sequencing (study group). The sequencing data were used to select several microRNAs that correlated with 12month recurrences after AF ablation. Those microRNAs were validated by digital droplet PCR in samples from remaining 90 patients. All patients underwent pulmonary vein isolation (RF ablation, contact force catheter, electroanatomical system). The endpoint of the study was the 12-month AF recurrence rate; the overall recurrence rate was 42.5%. In total, levels of 34 miRNAs were significantly different in sera from patients with Af recurrence compared to patients without Af recurrence. Six microRnAs (miR-183-5p, miR-182-5p, miR-32-5p, miR-107, miR-574-3p, and miR-144-3p) were validated in the whole group. Data from the validation group did not confirm the observations from the study group, as no significant differences were found between miRNAs serum levels in patients with and without recurrences 12 months after AF ablation.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum microRNA in patients undergoing atrial fibrillation ablation

Kiliszek

Maciak

Maciejak

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Recent studies indicated that miRs function as important regulators that participates in DM-induced atrial brosis 35 . The role of miR-21 in the pathogenesis of atrial brosis has been illuminated, and increased miR-21 expression was correlated positively with atrial brosis or brotic gene expression [20][21][22] signaling pathway by decrease CADM1 expression 58 . In our mice diabetic model, we also found that miR-21 KO manifested a decreased atrial brosis as well as brotic gene expression.…”

Section: Discussionmentioning

confidence: 99%

“…Their main function is to regulate post-transcriptional regulation of target genes expression by binding to the 3' untranslated region (3'-UTR) 19 . MicroRNA-21 (miR-21) has been shown to be associated with atrial brosis in previous studies [20][21][22] . But most of its mechanisms focused on the damage of cardiomyocytes and the activation of broblasts.…”

Section: Introductionmentioning

confidence: 99%

MiR-21-3p regulation FGFR1/FGF21/PPARγ pathway induces atrial fibrosis by targeting FGFR1 in diabetes

Pan¹,

Lin

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: A relationship between the abundance of epicardial adipose tissue (EAT) and the risk of atrial fibrosis and atrial fibrillation (AF) in diabetes mellitus (DM) has been reported. And previous studies have shown that MicroRNA-21 (miR-21) is a regulatory factor in atrial fibrosis and AF. The aim of this study was to examine the role of different subtypes of miR-21 in EAT browning and atrial fibrosis under hyperglycemia conditions.Methods: In vivo, C57BL/6 wild type (WT) and miR-21 knockout (KO) mice were used to establish the diabetic model by intraperitoneal injection of streptozotocin (STZ). In vitro, the EAT adipocytes from miR-21 KO mice were cultured and transfected with miR-21-3p mimic or miR-21-5p mimic and co-cultured with atrial fibroblasts in both HG or LG conditions. The browning of EAT and the fibrosis of fibroblasts were assessed by western blotting, immunofluorescence, Masson staining, and ELISA. The gain- and loss-of-function experiments were used to identified fibroblast growth factor receptor 1 (FGFR1) as the target gene of miR-21-3p.Results: In patients with DM and/or AF, serum hsa-miR-21-3p, instead of hsa-miR-21-5p, was significantly up-regulated. And miR-21 KO clearly ameliorated the atrial fibrosis in the diabetic mice. miR-21-3p as a key regulator that controls EAT browning and participates in atrial fibrosis under hyperglycemia conditions. Moreover, our gain- and loss-of-function experiments showed that FGFR1, as a direct target of miR-21-3p identified a regulatory pathway in EAT adipocytes. Conclusions: MiR-21-3p regulated EAT browning and participated the process of hyperglycemia-induced atrial fibrosis by targeting FGFR1.

show abstract

“…This process correlates with collagen, connective tissue growth factor, lysyl oxidase and Rac-1-GTPase contents in left atrial tissue [40]. Moreover, miR-21 regulates the signal transducer and activator of transcription 3 (STAT3) pathway, through which it induces inflammation-associated atrial fibrosis [41]. STAT3 is an important regulator of cell proliferation via downstream signaling molecule of Cell adhesion molecule 1 (CADM1).…”

Section: Association Between Microrna and Structural Remodeling Of Lamentioning

confidence: 99%

“…A significant correlation between the relationship of miR-21 serum concentrations and 1-year outcome after catheter ablation in patients with persistent AF has been described. It could be assumed that circulating miR-21 can be useful for stratifying patients and planning the procedure (e.g., performing a pulmonary vein isolation only in patients with very low miR-21 serum concentrations or planning extensive substrate modification in patients with high miR-21 levels) [41].…”

Section: Association Between Microrna and Structural Remodeling Of Lamentioning

confidence: 99%

Molecular Mechanisms, Diagnostic Aspects and Therapeutic Opportunities of Micro Ribonucleic Acids in Atrial Fibrillation

Böhm

Vachalcová²,

Snopek

et al. 2020

IJMS

View full text Add to dashboard Cite

Micro ribonucleic acids (miRNAs) are short non-coding RNA molecules responsible for regulation of gene expression. They are involved in many pathophysiological processes of a wide spectrum of diseases. Recent studies showed their involvement in atrial fibrillation. They seem to become potential screening biomarkers for atrial fibrillation and even treatment targets for this arrhythmia. The aim of this review article was to summarize the latest knowledge about miRNA and their molecular relation to the pathophysiology, diagnosis and treatment of atrial fibrillation.

show abstract

Circulating MicroRNA-21 Correlates With Left Atrial Low-Voltage Areas and Is Associated With Procedure Outcome in Patients Undergoing Atrial Fibrillation Ablation

Abstract: Circulating miR-21 correlates with left atrial LVAs and is associated with procedure outcome in patients with persistent AF undergoing ablation.

Cited by 54 publications

References 36 publications

Serum microRNA in patients undergoing atrial fibrillation ablation

Serum microRNA in patients undergoing atrial fibrillation ablation

MiR-21-3p regulation FGFR1/FGF21/PPARγ pathway induces atrial fibrosis by targeting FGFR1 in diabetes

Molecular Mechanisms, Diagnostic Aspects and Therapeutic Opportunities of Micro Ribonucleic Acids in Atrial Fibrillation

Contact Info

Product

Resources

About